TY - JOUR
T1 - Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines
AU - Recupero, Daniele
AU - Daniele, Lorenzo
AU - Marchiò, Caterina
AU - Molinaro, Luca
AU - Castellano, Isabella
AU - Cassoni, Paola
AU - Righi, Alberto
AU - Montemurro, Filippo
AU - Sismondi, Piero
AU - Biglia, Nicoletta
AU - Viale, Giuseppe
AU - Risio, Mauro
AU - Sapino, Anna
PY - 2013/2
Y1 - 2013/2
N2 - A subgroup of HER2-overexpressing breast tumours co-expresses p95 HER2, a truncated HER2 receptor that retains a functional HER2 kinase domain but lacks the extracellular domain, thus impairing trastuzumab binding. We evaluated p95HER2 expression in 99 frozen breast carcinoma samples by western blot analysis. The HER2-positive cell line BT474 treated with pervanadate or pronase was used as a positive control for p95HER2 expression. Immunohistochemistry was performed on parallel formalin-fixed, paraffin-embedded sections of the same case series using antibodies directed against either the intra- or extra-cellular binding domain of HER2. In particular, biotinylated trastuzumab (BiotHER) was used to evaluate the binding capacity of the humanized antibody. To avoid a subjective evaluation of the score values and the percentage of immunostained cells, the slides were scanned and automatically analysed. The number of cases with HER2 overexpression (score 3+) and HER2 gene amplification was higher in the p185HER2-positive/ p95HER2-positive samples than in the p185HER2-positive/ p95HER2-negative group. Automated analysis confirmed a significantly higher percentage of 3+ scored cells in p95HER2-positive cases. Conversely, the percentage of 2+ scored cells was higher in p95 HER2-negative cases. The status of the HER2 extracellular domain was then studied using flow cytometry on BT474 cells after pronase enzymatic digestion using trastuzumab and pertuzumab, while the presence of HER2-HER3 dimers was studied using a proximity-ligation assay. In vitro experiments showed that short-term pronase digestion of BT474 cells produced two HER2 fragments (of 95 and 150 kDa, detectable in tissue specimens as well), increased the binding affinity of trastuzumab, reduced the rate of HER2-HER3 dimers, and did not interfere with pertuzumab-binding capacity. In conclusion, the presence of p95HER2 as detected by western blot analysis does not compromise the immunohistochemical detection of HER2. Our data suggest that a reduction of the receptor steric hindrance as induced by enzymatic shedding may facilitate the binding capacity of trastuzumab.
AB - A subgroup of HER2-overexpressing breast tumours co-expresses p95 HER2, a truncated HER2 receptor that retains a functional HER2 kinase domain but lacks the extracellular domain, thus impairing trastuzumab binding. We evaluated p95HER2 expression in 99 frozen breast carcinoma samples by western blot analysis. The HER2-positive cell line BT474 treated with pervanadate or pronase was used as a positive control for p95HER2 expression. Immunohistochemistry was performed on parallel formalin-fixed, paraffin-embedded sections of the same case series using antibodies directed against either the intra- or extra-cellular binding domain of HER2. In particular, biotinylated trastuzumab (BiotHER) was used to evaluate the binding capacity of the humanized antibody. To avoid a subjective evaluation of the score values and the percentage of immunostained cells, the slides were scanned and automatically analysed. The number of cases with HER2 overexpression (score 3+) and HER2 gene amplification was higher in the p185HER2-positive/ p95HER2-positive samples than in the p185HER2-positive/ p95HER2-negative group. Automated analysis confirmed a significantly higher percentage of 3+ scored cells in p95HER2-positive cases. Conversely, the percentage of 2+ scored cells was higher in p95 HER2-negative cases. The status of the HER2 extracellular domain was then studied using flow cytometry on BT474 cells after pronase enzymatic digestion using trastuzumab and pertuzumab, while the presence of HER2-HER3 dimers was studied using a proximity-ligation assay. In vitro experiments showed that short-term pronase digestion of BT474 cells produced two HER2 fragments (of 95 and 150 kDa, detectable in tissue specimens as well), increased the binding affinity of trastuzumab, reduced the rate of HER2-HER3 dimers, and did not interfere with pertuzumab-binding capacity. In conclusion, the presence of p95HER2 as detected by western blot analysis does not compromise the immunohistochemical detection of HER2. Our data suggest that a reduction of the receptor steric hindrance as induced by enzymatic shedding may facilitate the binding capacity of trastuzumab.
KW - breast cancer
KW - HER2
KW - p95
KW - pronase
KW - trastuzumab binding site
KW - western blot
UR - http://www.scopus.com/inward/record.url?scp=84872971201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872971201&partnerID=8YFLogxK
U2 - 10.1002/path.4074
DO - 10.1002/path.4074
M3 - Article
C2 - 22806884
AN - SCOPUS:84872971201
VL - 229
SP - 390
EP - 399
JO - Journal of Pathology
JF - Journal of Pathology
SN - 0022-3417
IS - 3
ER -